ClinicalTrials.gg
CompletedNCT04975438Updated Aug 28, 2025Results posted

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

A Phase 1 interventional study of GSK1070806 and Placebo in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.

Enrollment
11th of 18
34 · median 42
Started
2021
the only one that year
Phase 1
9 of 19
none open now
Registered
15th of 19
by date

Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 9 in phase 1, and was the 15th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Dermatitis, Atopic by GlaxoSmithKline as a file.
02

Study summary

This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

Keywords

  • Eczema activity severity index
  • GSK1070806
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe AtD (confirmed by a dermatologist) according to the Hannifin and Rajka criteria or Eichenfield revised criteria.
  • Onset of AtD symptoms occurring at least 6 months prior to Screening, with stable disease for at least 1 month prior to Screening.
  • Eczema Activity Severity Index greater than or equal to (>=)16; Investigator Global Assessment score >=3.
  • Group 1- Biologic Naïve: Topical Treatment: Documented recent history (within 6 months before Screening) of: a) either an inadequate response (IR) to out-patient treatment with at least one topical treatment (intermittent topical , topical calcineurin inhibitor), topical inhibitors or Phosphodiesterase 4 inhibitor (Crisaborole); b) or that topical treatments were otherwise not recommended.
  • Group 2- Dupilumab-Inadequate Responder: Documented history of an IR to dupilumab: a) either following at least 16 weeks of treatment according to the Investigator's judgement; b) or intolerant to dupilumab owing to adverse events.

Exclusion criteria

Exclusion Criteria:

  • Other than AtD, the presence of a significant skin morbidity that will influence the Investigator's ability to assess the severity of the disease (e.g. psoriasis, confirmed or suspected cutaneous T-cell lymphoma, bullous disease, fixed drug reaction and Stevens Johnson Syndrome).
  • Participants with any uncontrolled medical conditions, other than AtD, that in the opinion of the investigator puts the participant at unacceptable risk or will likely interfere with study assessments or data integrity. Other medical conditions should be stable at the time of screening and be expected to remain stable for the duration of the study.
  • Treatment with biologic agents ( and marketed monoclonal antibodies) within 12 weeks or 5 pharmacokinetic half-lives (whichever is longer) prior dosing on Day 1.
  • Treatment with Janus Activated Kinase inhibitors (e.g. baricitinib, upadacitinib) within 4 weeks or 5 half-lives (whichever is longer) prior to dosing on Day 1.
  • Mycophenolate mofetil, azathioprine, methotrexate, or calcineurin inhibitors within 4 weeks of Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group 1: GSK1070806

    Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.

    Drug: GSK1070806

  • Placebo comparator
    Group 1: Placebo

    Participants received Placebo as intravenous infusion on Day 1.

    Drug: Placebo

  • Experimental
    Group 2: Dupilumab-IR with GSK1070806

    Participants received a single dose of 2 mg/kg GSK1070806 as intravenous infusion on Day 1.

    Drug: GSK1070806

  • Placebo comparator
    Group 2: Dupilumab IR with Placebo

    Participants received Placebo as intravenous infusion on Day 1.

    Drug: Placebo

Interventions

  • GSK1070806 will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. Posterior Median presented from Bayesian analysis under the hypothetical strategy. The percent change from baseline in the EASI score at week 12 in group 1 is reported here. Data reported as 'Median' refers to 'Posterior Median' and '95% Confidence Interval' refers to '95% Credible Interval'.

    Time frame: Baseline (Day 1) and at Week 12

Secondary outcomes

  1. Change From Baseline in EASI Score at Week 12 in Group 1

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. Posterior Median presented from Bayesian analysis under the hypothetical strategy. The change from baseline in the EASI score at week 12 in group 1 is reported here. Data reported as 'Median' refers to 'Posterior Median' and '95% Confidence Interval' refers to '95% Credible Interval'.

    Time frame: Baseline (Day 1) and at Week 12

  2. Number of Participants Achieving EASI-50, ≥ 50% Reduction in EASI Score at Week 12 in Group 1

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-50 responder is defined as a participant who achieves a ≥ 50% improvement from baseline in the EASI score.

    Time frame: At Week 12

  3. Number of Participants Achieving EASI-75, ≥ 75% Reduction in EASI Score at Week 12 in Group 1

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.

    Time frame: At Week 12

  4. Number of Participants Achieving EASI-90, ≥ 90% Reduction in EASI Score at Week 12 in Group 1

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.

    Time frame: At Week 12

  5. Number of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 12 in Group 1

    The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0-clear, 1-almost clear, 2-mild, 3-moderate, and 4- severe. Higher score indicates severity of disease. A Responder is defined as a participant who had an IGA score of 0 or 1 at each visit.

    Time frame: At Week 12

  6. Percent Change From Baseline in EASI Score at Week 12 in Group 2

    EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. NA indicate that data is not available since only one participant was analyzed, therefore Standard Deviation (SD) was not derived.

    Time frame: Baseline (Day 1) and at Week 12

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Groups 1 and 2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations as per investigator's medical or scientific judgment.

    Time frame: Up to Week 24

  8. Number of Participants With Worst Case Vital Signs Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

    Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate (PR) and body temperature were measured after resting for at least 5 minutes in semi-supine position. PCI ranges- SBP (millimeters of mercury\[mmHg\]): \<85 (low) or \>160 (high), DBP (mmHg): \<45 (low) or \>100 (high), PR (beats per minute): \<40 (low) or \>110 (high) and body temperature (degrees Celsius) \<=35.5 (low) or \>38.0 (high). Participants with worst case results relative to PCI criteria and who had values "to high" are reported here. Participants with a missing baseline value are assumed to have a within range value.

    Time frame: Up to Week 24

  9. Number of Participants With Worst Case 12-lead Electrocardiogram (ECG) Post-Baseline Relative to Baseline - Groups 1 and 2

    Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Participants with clinically significant changes relative to baseline are reported here. Clinically significant findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Up to Week 24

  10. Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline - Groups 1 and 2

    Urine samples were collected to assess urine glucose, bilirubin, protein, occult blood, Leukocyte Esterase and ketones using dipstick method. Participants with clinically significant changes relative to baseline are reported here. Clinically significant findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as the latest pre-dose assessment.

    Time frame: Up to Week 24

  11. Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

    Blood samples were collected for analysis of chemistry parameters. PCI ranges were \>3\*Upper limit of normal (ULN) units per liter (U/L)(Alanine Aminotransferase \[ALT\]), \>3\*ULN (U/L) (Aspartate Aminotransferase (\[AST\]), \>2\*ULN (Alkaline Phosphatase \[ALP\]) (U/L), \>2\*ULN (micromoles per liter) (bilirubin), \<3 or \>6.5 mmol/L (potassium), \<130 or \>160 mmol/L (sodium), \<1.5 or \>3.25 mmol/L (Corrected Calcium) and \>40 mmol/L (Urea). Participants with worst case results relative to PCI criteria and who had values "to high" are reported here. Participants with a missing baseline value are assumed to have a within range value.

    Time frame: Up to Week 24

  12. Number of Participants With Worst Case Hematology Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

    Blood samples were collected for analysis of hematology parameters. The ranges for the hematology parameters are as follows: Hematocrit \[High \>0.54 Proportion of red blood cells in blood, Low \<0.1 Proportion of red blood cells in blood\], Haemoglobin \[Higher: \> 185 grams/Litre (g/L) Low: less than (\<) 100 g/L \], Lymphocytes \[\<0.8 10\^9/L\], Neutrophils \[\<1.5 10\^9/L\], Platelets \[High: \> 999 10\^9/ L and Low: \< 100 10\^9/ L\] and White blood cells \[Low:\<2 10\^9/L\]. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' \& 'To High', so the percentages may not add to 100%.

    Time frame: Up to Week 25

  13. Number of Participants With Anti-drug Antibodies (ADA)- Groups 1 and 2

    Serum samples were analyzed for the presence of antibodies using a validated assay method. The treatment emergent ADA assay results up to week 24 are reported.

    Time frame: Up to Week 24

07

Results

Posted Jul 23, 2024

Participant flow

A total of 34 participants were enrolled at different centers in Canada and United States.

Participant flow — Overall Study
MilestoneGroup 1: GSK1070806Group 1: PlaceboGroup 2: Dupilumab- Inadequate Responders (IR) With GSK1070806Group 2: Dupilumab IR With Placebo
Started201031
Completed181021
Not completed2010
Withdrew: Lost to follow-up1010
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryPercent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. Posterior Median presented from Bayesian analysis under the hypothetical strategy. The percent change from baseline in the EASI score at week 12 in group 1 is reported here. Data reported as 'Median' refers to 'Posterior Median' and '95% Confidence Interval' refers to '95% Credible Interval'.

Time frame:
Baseline (Day 1) and at Week 12
Reported as:
Median · Percent Change
Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1
Percent ChangeGroup 1: GSK1070806Group 1: Placebo
Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1-66.11 (-78.65 to -53.54)-32.81 (-46.59 to -20.34)
Statistical analysis
  • Group 1: GSK1070806 vs Group 1: Placebo · Posterior median difference: -33.21 · 95% CI -50.96 to -14.84The posterior median of the difference (GSK1070806 - placebo) and 95% credible interval in PCFB in the EASI is presented. Analysis was performed using Bayesian analysis under the hypothetical strategy using an informative prior (robust MAP prior).
SecondaryChange From Baseline in EASI Score at Week 12 in Group 1

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. Posterior Median presented from Bayesian analysis under the hypothetical strategy. The change from baseline in the EASI score at week 12 in group 1 is reported here. Data reported as 'Median' refers to 'Posterior Median' and '95% Confidence Interval' refers to '95% Credible Interval'.

Time frame:
Baseline (Day 1) and at Week 12
Reported as:
Median · Scores on a Scale
Change From Baseline in EASI Score at Week 12 in Group 1
Scores on a ScaleGroup 1: GSK1070806Group 1: Placebo
Change From Baseline in EASI Score at Week 12 in Group 1-16.83 (-20.30 to -13.36)-7.15 (-12.12 to -2.20)
Statistical analysis
  • Group 1: GSK1070806 vs Group 1: Placebo · Posterior median difference: -9.68 · 95% CI -15.70 to -3.60The posterior median of the difference (GSK1070806 - placebo) and 95% credible interval in PCFB in the EASI is presented. Analysis was performed using Bayesian analysis with vague priors and adjusting for baseline EASI.
SecondaryNumber of Participants Achieving EASI-50, ≥ 50% Reduction in EASI Score at Week 12 in Group 1

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-50 responder is defined as a participant who achieves a ≥ 50% improvement from baseline in the EASI score.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving EASI-50, ≥ 50% Reduction in EASI Score at Week 12 in Group 1
ParticipantsGroup 1: GSK1070806Group 1: Placebo
Responder143
Non-responder56
SecondaryNumber of Participants Achieving EASI-75, ≥ 75% Reduction in EASI Score at Week 12 in Group 1

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the EASI score.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving EASI-75, ≥ 75% Reduction in EASI Score at Week 12 in Group 1
ParticipantsGroup 1: GSK1070806Group 1: Placebo
Responder71
Non-responder128
SecondaryNumber of Participants Achieving EASI-90, ≥ 90% Reduction in EASI Score at Week 12 in Group 1

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. The EASI-90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the EASI score.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving EASI-90, ≥ 90% Reduction in EASI Score at Week 12 in Group 1
ParticipantsGroup 1: GSK1070806Group 1: Placebo
Responder51
Non-responder148
SecondaryNumber of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 12 in Group 1

The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0-clear, 1-almost clear, 2-mild, 3-moderate, and 4- severe. Higher score indicates severity of disease. A Responder is defined as a participant who had an IGA score of 0 or 1 at each visit.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 12 in Group 1
ParticipantsGroup 1: GSK1070806Group 1: Placebo
Almost Clear (1)41
Clear (0)10
SecondaryPercent Change From Baseline in EASI Score at Week 12 in Group 2

EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % body surface area with AD in body region: 0 (0%), 1=1-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100% The final EASI score was obtained by weight-averaging these 4 scores and scores ranged from 0 to 72, with higher scores= more severe or extensive condition. NA indicate that data is not available since only one participant was analyzed, therefore Standard Deviation (SD) was not derived.

Time frame:
Baseline (Day 1) and at Week 12
Reported as:
Mean · Percent Change
Percent Change From Baseline in EASI Score at Week 12 in Group 2
Percent ChangeGroup 2: Dupilumab-Inadequate Responders (IR) With GSK1070806Group 2: Dupilumab IR With Placebo
Percent Change From Baseline in EASI Score at Week 12 in Group 2-94.213 ± 8.1841-38.868 ± NA
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Groups 1 and 2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations as per investigator's medical or scientific judgment.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Adverse Events106
Serious Adverse Events00
SecondaryNumber of Participants With Worst Case Vital Signs Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate (PR) and body temperature were measured after resting for at least 5 minutes in semi-supine position. PCI ranges- SBP (millimeters of mercury\[mmHg\]): \<85 (low) or \>160 (high), DBP (mmHg): \<45 (low) or \>100 (high), PR (beats per minute): \<40 (low) or \>110 (high) and body temperature (degrees Celsius) \<=35.5 (low) or \>38.0 (high). Participants with worst case results relative to PCI criteria and who had values "to high" are reported here. Participants with a missing baseline value are assumed to have a within range value.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Vital Signs Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Diastolic Blood Pressure (mmHg), Worst Case Post-Baseline,To Low00
Diastolic Blood Pressure (mmHg),Worst Case Post-Baseline, To w/in Range or No Change2210
Diastolic Blood Pressure (mmHg),Worst Case Post-Baseline, To High11
Pulse Rate (beats/min),Worst Case Post-Baseline,To Low00
Pulse Rate (beats/min),Worst Case Post-Baseline, To w/in Range or No Change2311
Pulse Rate (beats/min),Worst Case Post-Baseline, To High00
Systolic Blood Pressure (mmHg),Worst Case Post-Baseline,To Low00
Systolic Blood Pressure (mmHg),Worst Case Post-Baseline, To w/in Range or No Change2211
Systolic Blood Pressure (mmHg),Worst Case Post-Baseline, To High10
Temperature (C),Worst Case Post-Baseline,To Low10
Temperature (C),Worst Case Post-Baseline, To w/in Range or No Change2211
Temperature (C), Worst Case Post-Baseline, To High00
SecondaryNumber of Participants With Worst Case 12-lead Electrocardiogram (ECG) Post-Baseline Relative to Baseline - Groups 1 and 2

Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Participants with clinically significant changes relative to baseline are reported here. Clinically significant findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Worst Case 12-lead Electrocardiogram (ECG) Post-Baseline Relative to Baseline - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Number of Participants With Worst Case 12-lead Electrocardiogram (ECG) Post-Baseline Relative to Baseline - Groups 1 and 200
SecondaryNumber of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline - Groups 1 and 2

Urine samples were collected to assess urine glucose, bilirubin, protein, occult blood, Leukocyte Esterase and ketones using dipstick method. Participants with clinically significant changes relative to baseline are reported here. Clinically significant findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Baseline was defined as the latest pre-dose assessment.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline - Groups 1 and 200
SecondaryNumber of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

Blood samples were collected for analysis of chemistry parameters. PCI ranges were \>3\*Upper limit of normal (ULN) units per liter (U/L)(Alanine Aminotransferase \[ALT\]), \>3\*ULN (U/L) (Aspartate Aminotransferase (\[AST\]), \>2\*ULN (Alkaline Phosphatase \[ALP\]) (U/L), \>2\*ULN (micromoles per liter) (bilirubin), \<3 or \>6.5 mmol/L (potassium), \<130 or \>160 mmol/L (sodium), \<1.5 or \>3.25 mmol/L (Corrected Calcium) and \>40 mmol/L (Urea). Participants with worst case results relative to PCI criteria and who had values "to high" are reported here. Participants with a missing baseline value are assumed to have a within range value.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Chemistry Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Alanine Aminotransferase (IU/L),Worst Case Post-Baseline,To Low00
Alanine Aminotransferase (IU/L),Worst Case Post-Baseline,To W/in Range or No Change2211
Alanine Aminotransferase (IU/L),Worst Case Post-Baseline,To High10
Albumin (g/L),Worst Case Post-Baseline,To Low00
Albumin (g/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Albumin (g/L),Worst Case Post-Baseline,,To High00
Alkaline Phosphatase (IU/L),Worst Case Post-Baseline,To Low00
Alkaline Phosphatase (IU/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Alkaline Phosphatase (IU/L),Worst Case Post-Baseline,,To High00
Aspartate Aminotransferase (IU/L),Worst Case Post-Baseline,To Low00
Aspartate Aminotransferase (IU/L),Worst Case Post-Baseline,To W/in Range or No Change2210
Aspartate Aminotransferase (IU/L),Worst Case Post-Baseline,,To High11
Bilirubin (umol/L),Worst Case Post-Baseline,To Low00
Bilirubin (umol/L),Worst Case Post-Baseline,To W/in Range or No Change00
Bilirubin (umol/L),Worst Case Post-Baseline,To High2311
Calcium Corrected for Albumin (mmol/L),Worst Case Post-Baseline,To Low00
Calcium Corrected for Albumin (mmol/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Calcium Corrected for Albumin (mmol/L),Worst Case Post-Baseline,To High00
Potassium (mmol/L),Worst Case Post-Baseline,To Low00
Potassium (mmol/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Potassium (mmol/L),Worst Case Post-Baseline,To High00
Sodium (mmol/L),Worst Case Post-Baseline,To Low20
Sodium (mmol/L),Worst Case Post-Baseline,To W/in Range or No Change2111
Sodium (mmol/L),Worst Case Post-Baseline,To High00
Urea (mmol/L),Worst Case Post-Baseline,To Low00
Urea (mmol/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Urea (mmol/L),Worst Case Post-Baseline,To High00
SecondaryNumber of Participants With Worst Case Hematology Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2

Blood samples were collected for analysis of hematology parameters. The ranges for the hematology parameters are as follows: Hematocrit \[High \>0.54 Proportion of red blood cells in blood, Low \<0.1 Proportion of red blood cells in blood\], Haemoglobin \[Higher: \> 185 grams/Litre (g/L) Low: less than (\<) 100 g/L \], Lymphocytes \[\<0.8 10\^9/L\], Neutrophils \[\<1.5 10\^9/L\], Platelets \[High: \> 999 10\^9/ L and Low: \< 100 10\^9/ L\] and White blood cells \[Low:\<2 10\^9/L\]. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' \& 'To High', so the percentages may not add to 100%.

Time frame:
Up to Week 25
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Hematology Results by Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline - Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Hematocrit (fraction of 1),Worst Case Post-Baseline,To Low00
Hematocrit (fraction of 1),Worst Case Post-Baseline,To W/in Range or No Change2211
Hematocrit (fraction of 1),Worst Case Post-Baseline,To High10
Hemoglobin (g/L),Worst Case Post-Baseline,To Low20
Hemoglobin (g/L),Worst Case Post-Baseline,To W/in Range or No Change2111
Hemoglobin (g/L),Worst Case Post-Baseline,To High00
Leukocytes (10^9/L),Worst Case Post-Baseline,To Low00
Leukocytes (10^9/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Leukocytes (10^9/L),Worst Case Post-Baseline,To High00
Lymphocytes (10^9/L),Worst Case Post-Baseline,To Low22
Lymphocytes (10^9/L),Worst Case Post-Baseline,To W/in Range or No Change219
Lymphocytes (10^9/L),Worst Case Post-Baseline,To High00
Neutrophils (10^9/L),Worst Case Post-Baseline,To Low20
Neutrophils (10^9/L),Worst Case Post-Baseline,To W/in Range or No Change2111
Neutrophils (10^9/L),Worst Case Post-Baseline,To High00
Platelets (10^9/L),Worst Case Post-Baseline,To Low00
Platelets (10^9/L),Worst Case Post-Baseline,To W/in Range or No Change2311
Platelets (10^9/L),Worst Case Post-Baseline,To High00
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)- Groups 1 and 2

Serum samples were analyzed for the presence of antibodies using a validated assay method. The treatment emergent ADA assay results up to week 24 are reported.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA)- Groups 1 and 2
ParticipantsGroup 1 and 2: GSK1070806Group 1 and 2: Placebo
Number of Participants With Anti-drug Antibodies (ADA)- Groups 1 and 200

Adverse events

Collected over From Day 1 and up to Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK10708060/23 (0%)0/23 (0%)10/23 (43.5%)
Placebo0/11 (0%)0/11 (0%)6/11 (54.5%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventGSK1070806Placebo
Dermatitis atopicSkin and subcutaneous tissue disorders0/232/11
HeadacheNervous system disorders1/232/11
NasopharyngitisInfections and infestations0/232/11
COVID-19Infections and infestations2/231/11
ChillsGeneral disorders0/231/11
Cold sweatSkin and subcutaneous tissue disorders0/231/11
InsomniaPsychiatric disorders0/231/11
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/231/11
Seborrhoeic dermatitisSkin and subcutaneous tissue disorders0/231/11
SunburnInjury, poisoning and procedural complications0/231/11

Baseline characteristics

The analysis population comprised of enrolled analysis set who were assigned to study intervention. Because of the small sample size, summary of baseline/demographics categorical variables are presented as de-identified to prevent risk of participant re-identification.

Age, Customized
Age, Customized(Participants)Group 1: GSK1070806Group 1: PlaceboGroup 2: Dupilumab-IR With GSK1070806Group 2: Dupilumab IR With PlaceboTotal
De-identified20103134
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Group 1: GSK1070806Group 1: PlaceboGroup 2: Dupilumab-IR With GSK1070806Group 2: Dupilumab IR With PlaceboTotal
De-identified20103134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: GSK1070806Group 1: PlaceboGroup 2: Dupilumab-IR With GSK1070806Group 2: Dupilumab IR With PlaceboTotal
De-identified20103134
08

Study locations

11 sites
  • GSK Investigational Site
    North Little Rock, Arkansas 72117, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Troy, Michigan 48084, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73118, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • GSK Investigational Site
    San Antonio, Texas 78218, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Edmonton, Alberta T6G 1C3, Canada
  • GSK Investigational Site
    London, Ontario N6A 5R9, Canada
  • GSK Investigational Site
    London, Ontario N6H 5L5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2022, 13 months.

Results were first posted in Jul 2024, 1 year 7 months after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 13 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 23, 2021
StartActual
Nov 18, 2021
Primary completionActual
Dec 19, 2022
CompletionActual
Mar 13, 2023
Results first posted
Jul 23, 2024
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04975438
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 23, 2021
Start date
Nov 18, 2021
Primary completion
Dec 19, 2022
Completion
Mar 13, 2023
Results posted
Jul 23, 2024
Last update
Aug 28, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1070806

Start the discussion